Overview of Сутент

Property	Description
Active Ingredient	Sunitinib (Sunitinib malate)
Form	Hard gelatin capsule
Pharmacological Class	Multi-targeted Receptor Tyrosine Kinase (RTK) Inhibitor
Administration Route	Oral (by mouth)
Origin	Synthetic small-molecule compound

What Type of Medicine is Сутент (Sunitinib)?

Сутент is the trade name for the international nonproprietary name (INN) Sunitinib, which is classified as a modern antineoplastic agent delivered as a specialized Targeted Therapy. Sunitinib belongs to the pharmacological class known as Multi-targeted Receptor Tyrosine Kinase (RTK) Inhibitors. This classification indicates the compound is designed to selectively interfere with specific molecular pathways required for tumor survival and growth. This mechanism has been extensively studied and clinically recognized as a key strategy in combating advanced diseases where uncontrolled cell signaling is central. Sunitinib's status as a targeted therapy differentiates it from traditional cytotoxic chemotherapy by focusing treatment on molecular vulnerabilities.

Composition, Form, and Origin of Sunitinib

The active component in this medication is Sunitinib, a purely synthetic, small-molecule compound that is formulated as a hard gelatin capsule for oral administration. The medicine is a prescription-only (Rx) product and a single-ingredient product, containing only Sunitinib (often as Sunitinib malate) as the active pharmaceutical ingredient. The capsule form is a distinguishing feature, allowing for self-administration and differentiating it from therapies that require mandatory intravenous administration in a hospital setting. This oral route is supported by pharmacological studies confirming its reliable absorption profile.

General Purpose and Benefit of Targeted Inhibition

The general therapeutic purpose of Sunitinib is to effectively slow the proliferation of certain cancer cells and impede disease progression. It achieves this benefit through a dual mode of action: by blocking growth signals that drive abnormal cell multiplication and by acting as an Angiogenesis Inhibitor. This strategy of targeted inhibition is typically applied to adult patients with advanced disease. This approach is clinically established to help achieve disease stabilization by preventing rapid progression and denying the tumor the necessary resources, such as blood supply, to thrive.

What side effects are possible with Сутент?

Possible Side Effects and Safety Information

The safety profile of Sunitinib, as documented in official regulatory sources, involves a spectrum of adverse reactions categorized by their frequency and the organ systems they affect. The most Very Common events, as classified by the EMA SmPC and FDA labeling, include fatigue, diarrhea, mucositis/stomatitis, nausea, hypertension, hand-foot syndrome, and changes in taste (dysgeusia). These common effects are generally not cumulative, and hematological changes like thrombocytopenia and neutropenia are typically reversible.

Serious Adverse Reactions

The regulatory label highlights several risks classified as serious or potentially fatal. These include cardiac events (such as heart failure or myocardial infarction), severe hepatotoxicity (including liver failure), gastrointestinal perforation, and severe dermatologic toxicities (e.g., Stevens-Johnson Syndrome). Furthermore, hemorrhagic events and Thrombotic Microangiopathy (TMA) are recognized as clinically significant serious risks.

Safety Considerations and Monitoring

The official prescribing information mandates specific safety monitoring. Baseline and periodic assessments of Left Ventricular Ejection Fraction (LVEF), blood pressure, thyroid function tests, and urinary protein are required. Therapy interruption is recommended for patients undergoing major surgery due to potential impaired wound healing. Use is generally not recommended for patients with severe hepatic impairment (Child-Pugh Class C) as it has not been studied in this population, and the medicine can cause fetal harm if used during pregnancy.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory information for Sunitinib focuses on general supportive measures for managing an overdose, as no specific antidote is known to exist.

Domain
Documented Overdose Presentations	Accidental overdose has been reported, with manifestations noted as being consistent with the known safety profile of Sunitinib, or occasionally reported without adverse reactions.
Emergency-response Statements	Treatment of overdosage should consist of general supportive measures. Procedural options for eliminating unabsorbed drug, if clinically indicated, may include emesis or gastric lavage.

This lack of a specific antidote means that all suspected or confirmed cases of over-ingestion require immediate symptomatic and supportive treatment under the supervision of medical professionals. The official documentation refers to general guidance when stating that urgent medical attention must be sought in all cases of suspected overdose.

Resulting Overdose Structure

Official overdose statements:

The official treatment for Sunitinib overdosage is to use general supportive measures.
No specific antidote is known to counteract the effects of Sunitinib overdosage.
Elimination of unabsorbed drug may involve emesis or gastric lavage, if considered clinically appropriate.

Connection to the overall overdose profile: Regulatory documents define the Sunitinib overdose profile by mandating that general supportive measures constitute the entire treatment approach, as they explicitly state that no specific antidote is known. The clinical presentation of an overdose is expected to align with the drug's established side-effect profile. Consequently, the regulatory-mandated condition for seeking help is the initiation of immediate supportive and symptomatic treatment in a clinical setting.

Therapeutic Uses of Сутент

Quick Facts: Approved Therapeutic Domains

Gastrointestinal Stromal Tumor (GIST): Used in patients who have experienced disease progression or intolerance to imatinib mesylate.
Advanced Renal Cell Carcinoma (RCC): Indicated for the management of advanced forms of this type of kidney cancer.
Adjuvant RCC Treatment: Utilized in patients at a heightened risk of recurrence following surgical removal of the kidney (nephrectomy).
Pancreatic Neuroendocrine Tumors (pNET): Intended for the management of progressive, well-differentiated tumors that cannot be surgically removed (unresectable, locally advanced, or metastatic disease).

Сутент (Sutent) is a prescription medication utilized in oncology for several specific therapeutic domains. This treatment option is authorized to address certain types of cancer in adult patients.

The medication is indicated for the treatment of Gastrointestinal Stromal Tumor (GIST) in cases where patients have experienced disease progression or were unable to tolerate a previous treatment, imatinib mesylate. It is also a treatment option for individuals diagnosed with advanced Renal Cell Carcinoma (RCC), a form of kidney cancer.

Furthermore, this drug supports the adjuvant setting for adult patients considered to be at high risk of recurrent RCC following the surgical removal of the kidney. Lastly, it is indicated for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in individuals with locally advanced or metastatic disease that is considered unresectable.

Eligibility and Restrictions for Use

Who can and cannot use Сутент?

Eligibility for Сутент (Sunitinib) is strictly defined by regulatory authorities and centers on age, reproductive status, and specific pre-existing health conditions.

Population Group	Eligibility Status (Regulatory Basis)
Age Restriction	Indicated for adult patients only. Safety and efficacy have not been established in pediatric patients.
Hypersensitivity	Contraindicated in patients with known allergy to sunitinib or any of its excipients.
Pregnancy	Contraindicated due to the potential for fetal harm; women must use effective contraception during and for at least one month after treatment.
Lactation	Not recommended during treatment and for four weeks following the final dose.
Severe Hepatic Impairment	Use is not studied (e.g., Child-Pugh Class C); dosing recommendations cannot be established.
Renal Impairment	No starting dose adjustment is required for mild to severe renal impairment or end-stage renal disease (ESRD).

The medicine is officially approved for use only in the adult population for its labeled indications. Older adults generally require no adjustment, as comparative studies found no significant differences in use. Use requires caution and monitoring in patients with a history of specific cardiac conditions, as noted in the prescribing information.

What should I know about interactions with other medicines?

Interactions with other medicines and products — official regulatory information for Sunitinib

The official regulatory profile for Sunitinib is primarily defined by pharmacokinetic and pharmacodynamic interactions.

Interaction Scope

Category	Official Regulatory Documentation Statement
Medicinal product categories with documented interactions	Strong inhibitors and strong inducers of Cytochrome P450 3A4 (CYP3A4); Drugs known to prolong the QTc interval; Antidiabetic drugs.
Specific interacting medicines (if explicitly listed)	Strong CYP3A4 Inhibitor: Ketoconazole; Strong CYP3A4 Inducer: Rifampin; QTc Prolonging Drug: Lefamulin; Herbal Inducer: St. John's Wort.
Mechanistic basis of interactions (only if stated in label)	Pharmacokinetic Interaction: Sunitinib is metabolized by CYP3A4. Co-administration with CYP3A4 modulators alters Sunitinib's plasma concentrations. Pharmacodynamic Interaction: Additive risk of QTc interval prolongation and potential for hypoglycemia.
Timing-based interaction rules (if applicable)	No explicit, mandatory timing separation windows are specified for co-administration.
Population-specific interaction notes (if applicable)	Not studied in patients with severe hepatic impairment (Child-Pugh Class C).

Interaction-Related Restrictions

Avoid co-administration with strong CYP3A4 inhibitors or inducers where possible, as these significantly alter Sunitinib exposure.
Avoid consumption of Grapefruit or Grapefruit juice, which can increase plasma concentrations.
The combination with Lefamulin is a formally contraindicated combination due to heightened CYP3A4 and cardiac risk.
Enhanced monitoring of the QTc interval is required when Sunitinib is co-administered with other QTc prolonging drugs.

Connection to the overall interaction profile (2–4 sentences): Regulatory documents establish that the drug's interaction structure is based on its reliance on CYP3A4 metabolism, which governs the need for dose management or strict avoidance of strong enzyme modulators. The profile is further constrained by pharmacodynamic risks that necessitate enhanced monitoring, particularly for cardiac function and blood glucose control, when combined with specific agents.

Mechanism of Action

Dual Mechanism: Kinase Inhibition and Vascular Modulation

Sunitinib functions as a multi-targeted inhibitor by directly blocking the activity of several Receptor Tyrosine Kinases (RTKs), including KIT, FLT3, and the VEGFR/PDGFR family. This molecular action involves competitive binding to the receptors' ATP-binding pocket, which prevents the signal initiation (phosphorylation) and halts the downstream cascades (e.g., PI3K/AKT/mTOR) responsible for driving cell proliferation and survival. The core cellular consequence of this blockade is the suppression of cell proliferation signaling and the induction of programmed cell death (apoptosis).

The second mechanism involves the mechanistic inhibition of angiogenesis by blocking VEGFRs and PDGFRs on vascular support cells. By inhibiting these receptors, the drug disrupts the signaling required for vascular growth and maturation within the tissue mass. This disruption results in diminished blood flow and nutrient delivery to the tissue, which ultimately limits the resources available for continuous cellular multiplication.

Dosage and Administration Information

How to Use Sunitinib (Sutent) — Official Administration Guidelines

Sunitinib is an oral, prescription-only medication administered via hard gelatin capsules in strengths of 12.5 mg, 25 mg, 37.5 mg, and 50 mg. The official administration route is by mouth, and the capsules must be swallowed whole without being opened, chewed, or crushed.

Dosing and Scheduling

Official dosing is determined by the specific disease being treated. For Gastrointestinal Stromal Tumor (GIST) and advanced Renal Cell Carcinoma (RCC), the standard starting dose is 50 mg once daily. For Pancreatic Neuroendocrine Tumors (pNET), the standard starting dose is 37.5 mg once daily. The capsule may be taken with or without food.

The medication follows two distinct time schedules:

Cyclic Regimen: Used for GIST, advanced RCC, and adjuvant RCC. This involves taking the daily dose for 4 consecutive weeks, followed by a 2-week rest period. A complete cycle is 6 weeks.
Continuous Regimen: Used for pNET, involving continuous once-daily administration without a scheduled rest period.

Dose Management and Duration

If a dose is missed, patients should not take an additional dose; the next dose should be taken at the usual scheduled time. Dosage adjustments, typically in 12.5 mg increments or decrements, may be necessary based on individual tolerability or when co-administered with strong CYP3A4 inhibitors or inducers, as detailed in the official prescribing documents. Treatment duration is typically open-ended until disease progression, except in the adjuvant RCC setting, where use is limited to a maximum of nine 6-week cycles (approximately one year).

Recent Clinical Evidence

The drug's primary use, as investigated in research, is for the physical and mental symptoms associated with mild-to-moderate generalized anxiety disorder (GAD). Research has also explored its application in other anxiety and pain-related conditions.

Studies on Generalized Anxiety Disorder (GAD)

Multiple clinical trials reported findings examining changes in the severity of GAD symptoms compared to placebo.

Clinical Findings in GAD

Several placebo-controlled, double-blind trials investigated the substance across various populations. These studies primarily focused on measuring changes using the Hamilton Anxiety Rating Scale (HAM-A) and the Clinical Global Impression (CGI) scale.
One key study documented changes in the HAM-A scores observed after four weeks of treatment. The magnitude of change documented in the studies aligned with observations reported for established treatments (e.g., specific benzodiazepines and SSRIs) within the same trials.

Trial Administration

Most trials evaluated fixed and flexible dosing regimens. Trial protocols detailed a specific daily administration schedule.
The studies described protocols for managing participant discontinuation and noted that supervision was required during discontinuation.

Safety and Tolerability Profile

Commonly Documented Observations

The most frequently reported side effects were described as minor and temporary by study investigators in the studies that examined long-term use. These typically included nausea, dry mouth, dizziness, and headache.
The discontinuation rates due to adverse events were reported to be slightly higher than those for placebo. The rate of discontinuation due to adverse events was consistent with rates documented for similar pharmacologic categories.

Comparative Data

The substance was investigated in patient populations who have historically not responded to single-agent antidepressants. The available data from the reviewed studies were not sufficient to draw definitive conclusions regarding comparative long-term tolerability.

Other Investigational Uses

Off-label use is being evaluated in research for fibromyalgia and chronic neuropathic pain, and early trials have documented preliminary findings. These investigations are typically short-term, dose-finding studies, and evidence remains limited regarding long-term outcomes or definitive efficacy in these areas.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Сутент (FAQ)

Q: Does Сутент cure cancer, or does it slow it down?

A: According to regulatory documents, Sunitinib is an antineoplastic agent used to slow the progression of certain cancers. Official studies on the drug measure its benefit based on concepts like progression-free survival and overall survival time, rather than confirming a complete cure.

Q: How quickly does Сутент start working after I begin taking it?

A: After taking a single dose, the official product information indicates that the drug reaches its maximum concentration in the blood within 6 to 12 hours. However, the body typically achieves steady-state concentrations—where the drug level remains consistent—only after 10 to 14 days of continued daily administration.

Q: Does Сутент cause hair loss?

A: Yes, official drug information and adverse event reports list both hair loss (alopecia) and thinning of the hair as known side effects. This effect is described as a common observation in the official clinical trial data.

Q: Is Сутент safe for someone who has heart problems?

A: The drug is associated with a risk of cardiovascular events, including heart failure. Official warnings state that patients with a history of heart problems may be at a higher risk. Monitoring of heart function is specified in the official prescribing information for patients during treatment.

Q: Are the side effects of Сутент permanent?

A: The reversibility of all side effects is not guaranteed in the official documentation. While some effects, such as changes in blood cell counts, are often reversible once treatment stops, official documentation mentions that some serious effects may require specific patient management as determined by the healthcare provider.

Q: How long does the effect of Сутент last after I stop treatment?

A: Sunitinib is eliminated from the body slowly. According to regulatory pharmacokinetics data, the drug and its active metabolite (a substance it turns into) have a long half-life. This means it can take several days for the compound to be fully cleared from the body.

Q: What is the typical length of time a patient stays on Сутент?

A: For most advanced cancers, treatment typically continues for as long as the medicine is controlling the disease. Official guidelines specify that in the adjuvant setting for renal cell carcinoma, use is limited to a maximum total of nine 6-week cycles, which is about one year.

Q: Does Сутент interact with common vitamins or supplements?

A: Official drug documents specifically identify the herbal supplement St. John's wort as a strong enzyme inducer that should not be used with Sunitinib. Regulatory documents recommend that patients discuss all medications, vitamins, and supplements with their healthcare provider.

Q: What is the general success rate mentioned in studies for Сутент?

A: Regulatory studies do not quote a single 'success rate' but report measures of clinical benefit. These include the Objective Response Rate (ORR), which is the percentage of patients whose cancer shrinks significantly, and the median Progression-Free Survival (PFS) time, which are specific to the type of cancer being treated.

Q: Is Сутент used for cancer types other than kidney, liver, or pancreatic?

A: Official regulatory documents list the approved indications as Gastrointestinal Stromal Tumor (GIST), advanced Renal Cell Carcinoma (RCC) (including adjuvant use), and Pancreatic Neuroendocrine Tumors (pNET). The full list of approved uses is detailed in the official prescribing information.

Q: What happens if I accidentally take two doses of Сутент?

A: In cases of accidental overdosage, the official regulatory information states that there is no specific antidote. Treatment should consist of general supportive measures. In such an event, contacting a healthcare provider or emergency service is indicated.

Q: Does being on Сутент mean I have a compromised immune system?

A: Sunitinib can cause myelosuppression (a decrease in bone marrow activity), which includes low white blood cell counts, known as neutropenia. This condition can increase the risk for serious infection, and regular blood monitoring is a required part of the safety management.

Q: Can Сутент affect my ability to drive or operate machinery?

A: Official product information advises caution because the drug may cause side effects like fatigue and dizziness. Patients are advised to use caution when performing these activities.

Q: Is there a generic version of Сутент available?

A: Yes, regulatory records, such as the FDA's Approved Drug Products list (Orange Book), indicate that a generic version of Sunitinib malate for oral use has been approved.

Q: Can high blood pressure caused by Сутент be treated?

A: The hypertension (high blood pressure) that may be caused by the drug can typically be managed using standard blood pressure medications. If the condition is severe or persistent, the official prescribing information states that a dose interruption or reduction of Sunitinib may be necessary.

Q: Are there any long-term effects of taking Сутент that people should know about?

A: The official label highlights the potential for serious events, such as cardiac issues and thyroid dysfunction. These may require ongoing monitoring throughout the duration of treatment, which can be long-term for many patients.

Q: What are the common reasons why a doctor might discontinue Сутент treatment?

A: Treatment may be discontinued for several reasons noted in official documents. These include disease progression (the drug is no longer effective), the development of serious, unmanageable side effects (e.g., severe heart or liver toxicity), or to prepare for a major surgery.

Q: Does Сутент affect fertility in men or women?

A: Official information, based on animal studies, indicates that Sunitinib may compromise fertility in both males and females. Patients who are of reproductive potential often discuss this risk with their doctor before starting therapy.

Q: Is it common for people taking Сутент to lose their appetite?

A: Yes, the official list of adverse reactions reported in clinical trials includes loss of appetite (anorexia) as a common side effect experienced by patients.

Q: Are there any official patient support programs for people taking Сутент?

A: Official drug documentation, such as the Medication Guide, typically refers patients to the manufacturer's patient assistance or support programs. These programs may offer information on financial assistance or other resources for people taking the drug.

Q: How often do the serious side effects of Сутент occur in studies?

A: The official label includes tables detailing the incidence of serious side effects from clinical trials. These frequencies are reported numerically, often as a percentage of patients who experienced the specific event, and vary depending on the severity of the reaction.

Q: Is Сутент an immunosuppressant drug?

A: Sunitinib is not classified as an immunosuppressant, but it can cause a condition called myelosuppression. This involves a reduction in bone marrow activity, which can lead to low white blood cell counts and increase a patient's risk of developing a serious infection.

How should Сутент be stored and disposed of?

Storage and Disposal of Sutent (Sunitinib Malate) Capsules

Official regulatory guidelines define specific conditions for storing and disposing of Sutent capsules.

Storage Requirements

Sutent must be stored at a controlled room temperature of 25 C (77 F), with allowed temperature variations between 15 C and 30 C (59 F and 86 F). The product must be kept in its original container and stored strictly out of the reach of children.

Disposal Instructions

Unused or expired Sutent must not be disposed of using household methods, such as flushing down the toilet or pouring down a drain. Patients should consult a healthcare professional or pharmacist for guidance on proper disposal. Using a drug take-back program or following instructions from local waste authorities is recommended.

Сутент